原發性甲狀旁腺功能亢進的外科治療進展及展望_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

喻慶安 ,  代文杰

哈爾濱醫科大學附屬第一醫院甲狀腺外科（哈爾濱 150001）;

Corresponding?author：

代文杰, Email: davidhmu@163.com

Keywords：

DOI：

10.7507/1007-9424.202008037

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 喻慶安, 代文杰. 原發性甲狀旁腺功能亢進的外科治療進展及展望. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(10): 1192-1195. doi: 10.7507/1007-9424.202008037 Copy

1.	Bilezikian JP, Bandeira L, Khan A, <italic>et al</italic>. Hyperparathyroidism. Lancet, 2017, 69(10116): 1558.
2.	Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab, 2018, 32(5): 593-607.
3.	Lundgren E, Hagstr?m EG, Lundin J, <italic>et al</italic>. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening8 years ago. World J Surg, 2002, 26(8): 931-936.
4.	Pallan S, Rahman MO, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ, 2012, 344: e1013.
5.	Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med, 2004, 350(17): 1746-1751.
6.	Clarke BL. Epidemiology of primary hyperparathyroidism. J Clin Densitom, 2013, 16(1): 8-13.
7.	Bilezikian JP, Meng X, Shi Y, <italic>et al</italic>. Primary hyperparathyroidism in women: a tale of two cities–New York and Beijing. Int J Fertil Womens Med, 2000, 45(2): 158-165.
8.	Melton LJ 3rd. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res, 2002, 17(Suppl 2): N12-N17.
9.	Bilezikian JP, Cusano NE, Khan AA, <italic>et al</italic>. Primary hyperparathyroidism. Nat Rev Dis Primers, 2016, 2: 16033.
10.	Press DM, Siperstein AE, Berber E, <italic>et al</italic>. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery, 2013, 154(6): 1232-1238.
11.	Stokes VJ, Nielsen MF, Hannan FM, <italic>et al</italic>. Hypercalcemic disorders in children. J Bone Miner Res, 2017, 32(11): 2157-2170.
12.	Walker MD, Bilezikian JP. Primary hyperparathyroidism: recent advances. Curr Opin Rheumatol, 2018, 30(4): 427-439.
13.	Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol, 2018, 14(2): 115-125.
14.	Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med, 2011, 365(25): 2389-2397.
15.	Cetani F, Saponaro F, Borsari S, <italic>et al</italic>. Familial and hereditary forms of primary hyperparathyroidism. Front Horm Res, 2019, 51: 40-51.
16.	Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol, 2014, 386(1-2): 2-15.
17.	Ryan S, Courtney D, Timon C. Co-existent thyroid disease in patients treated for primary hyperparathyroidism: implications for clinical management. Eur Arch Otorhinolaryngol, 2015, 272(2): 419-423.
18.	Cuhaci N, Ozdemir D, Polat B, <italic>et al</italic>. Concomitant thyroid lesions in patients with primary hyperparathyroidism. Asian J Surg, 2017, 40(5): 338-344.
19.	Phillips DJ, Kutler DI, Kuhel WI. Incidental thyroid nodules in patients with primary hyperparathyroidism. Head Neck, 2014, 36(12): 1763-1765.
20.	Bentrem DJ, Angelos P, Talamonti MS, <italic>et al</italic>. Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism? Thyroid, 2002, 12(12): 1109-1112.
21.	Vargas-Ortega G, Balcázar-Hernández L, González-Virla B, <italic>et al</italic>. Symptomatic primary hyperparathyroidism as a risk factor for differentiated thyroid cancer. J Thyroid Res, 2018, 2018: 9461079.
22.	Wilhelm SM, Wang TS, Ruan DT, <italic>et al</italic>. The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg, 2016, 151(10): 959-968.
23.	Hindié E, Zanotti-Fregonara P, Tabarin A, <italic>et al</italic>. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J Nucl Med, 2015, 56(5): 737-744.
24.	Pata G, Casella C, Magri GC, <italic>et al</italic>. Financial and clinical implications of low-energy CT combined with <sup>99m</sup>Technetium-sestamibi SPECT for primary hyperparathyroidism. Ann Surg Oncol, 2011, 18(9): 2555-2563.
25.	Patel CN, Salahudeen HM, Lansdown M, <italic>et al</italic>. Clinical utility of ultrasound and <sup>99m</sup>Tc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. Clin Radiol, 2010, 65(4): 278-287.
26.	Hamidi M, Sullivan M, Hunter G, <italic>et al</italic>. 4D-CT is superior to ultrasound and sestamibi for localizing recurrent parathyroid disease. Ann Surg Oncol, 2018, 25(5): 1403-1409.
27.	中華醫學會外科學分會甲狀腺及代謝外科學組, 中國研究型醫院學會甲狀旁腺及骨代謝疾病專業委員會. 原發性甲狀旁腺功能亢進癥圍手術期處理中國專家共識 (2020版). 中國實用外科雜志, 2020, 40(6): 634-638.
28.	Lundstam K, Heck A, Godang K, <italic>et al</italic>. Effect of surgery <italic>versus</italic> observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study). J Bone Miner Res, 2017, 32(9): 1907-1914.
29.	Clarke BL. Asymptomatic primary hyperparathyroidism. Front Horm Res, 2019, 51: 13-22.
30.	Cansu GB, Y?lmaz N, ?zdem S, <italic>et al</italic>. Parathyroidectomy in asymptomatic primary hyperparathyroidism reduces carotid intima-media thickness and arterial stiffness. Clin Endocrinol (Oxf), 2016, 84(1): 39-47.
31.	?iprová H, Fry?ák Z, Sou?ek M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract, 2016, 22(3): 294-301.
32.	Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: a revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery, 2017, 161(1): 16-24.
33.	Laird AM, Libutti SK. Minimally invasive parathyroidectomy <italic>versus</italic> bilateral neck exploration for primary hyperparathyroidism. Surg Oncol Clin N Am, 2016, 25(1): 103-118.
34.	Norman J, Lopez J, Politz D. Abandoning unilateral parathyroidectomy: why we reversed our position after 15, 000 parathyroid operations. J Am Coll Surg, 2012, 214(3): 260-269.
35.	Kavanagh DO, Fitzpatrick P, Myers E, <italic>et al</italic>. A predictive model of suitability for minimally invasive parathyroid surgery in the treatment of primary hyperparathyroidism[corrected]. World J Surg, 2012, 36(5): 1175-1181.
36.	Thier M, Daudi S, Bergenfelz A, <italic>et al</italic>. Predictors of multiglandular disease in primary hyperparathyroidism. Langenbecks Arch Surg, 2018, 403(1): 103-109.
37.	Najafian A, Kahan S, Olson MT, <italic>et al</italic>. Intraoperative PTH may not be necessary in the management of primary hyperparathyroidism even with only one positive or only indeterminate preoperative localization studies. World J Surg, 2017, 41(6): 1500-1505.
38.	Bachar G, Mizrachi A, Hadar T, <italic>et al</italic>. Role of parathyroid hormone monitoring during parathyroidectomy. Head Neck, 2011, 33(12): 1754-1757.
39.	Wang W, Kong J, Nie M, <italic>et al</italic>. Primary hyperparathyroidism in Chinese children and adolescents: a single-centre experience at Peking Union Medical College Hospital. Clin Endocrinol (Oxf), 2017, 87(6): 865-873.
40.	Hsu SC, Levine MA. Primary hyperparathyroidism in children and adolescents: the Johns Hopkins Children’s Center experience 1984-2001. J Bone Miner Res, 2002, 17(Suppl 2): N44-N50.
41.	Mukherjee S, Bhadada SK, Arya AK, <italic>et al</italic>. Primary hyperparathyroidism in the young: comparison with adult primary hyperparathyroidism. Endocr Pract, 2018, 24(12): 1051-1056.
42.	Morris LF, Zelada J, Wu B, <italic>et al</italic>. Parathyroid surgery in the elderly. Oncologist, 2010, 15(12): 1273-1284.
43.	Hedb?ck G, Odén A. Increased risk of death from primary hyperparathyroidism–an update. Eur J Clin Invest, 1998, 28(4): 271-276.
44.	Hu Y, Cui M, Sun Z, <italic>et al</italic>. Clinical presentation, management, and outcomes of primary hyperparathyroidism during pregnancy. Int J Endocrinol, 2017, 2017: 3947423.

1. Bilezikian JP, Bandeira L, Khan A, <italic>et al</italic>. Hyperparathyroidism. Lancet, 2017, 69(10116): 1558.
2. Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab, 2018, 32(5): 593-607.
3. Lundgren E, Hagstr?m EG, Lundin J, <italic>et al</italic>. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening8 years ago. World J Surg, 2002, 26(8): 931-936.
4. Pallan S, Rahman MO, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ, 2012, 344: e1013.
5. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med, 2004, 350(17): 1746-1751.
6. Clarke BL. Epidemiology of primary hyperparathyroidism. J Clin Densitom, 2013, 16(1): 8-13.
7. Bilezikian JP, Meng X, Shi Y, <italic>et al</italic>. Primary hyperparathyroidism in women: a tale of two cities–New York and Beijing. Int J Fertil Womens Med, 2000, 45(2): 158-165.
8. Melton LJ 3rd. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res, 2002, 17(Suppl 2): N12-N17.
9. Bilezikian JP, Cusano NE, Khan AA, <italic>et al</italic>. Primary hyperparathyroidism. Nat Rev Dis Primers, 2016, 2: 16033.
10. Press DM, Siperstein AE, Berber E, <italic>et al</italic>. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery, 2013, 154(6): 1232-1238.
11. Stokes VJ, Nielsen MF, Hannan FM, <italic>et al</italic>. Hypercalcemic disorders in children. J Bone Miner Res, 2017, 32(11): 2157-2170.
12. Walker MD, Bilezikian JP. Primary hyperparathyroidism: recent advances. Curr Opin Rheumatol, 2018, 30(4): 427-439.
13. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol, 2018, 14(2): 115-125.
14. Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med, 2011, 365(25): 2389-2397.
15. Cetani F, Saponaro F, Borsari S, <italic>et al</italic>. Familial and hereditary forms of primary hyperparathyroidism. Front Horm Res, 2019, 51: 40-51.
16. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol, 2014, 386(1-2): 2-15.
17. Ryan S, Courtney D, Timon C. Co-existent thyroid disease in patients treated for primary hyperparathyroidism: implications for clinical management. Eur Arch Otorhinolaryngol, 2015, 272(2): 419-423.
18. Cuhaci N, Ozdemir D, Polat B, <italic>et al</italic>. Concomitant thyroid lesions in patients with primary hyperparathyroidism. Asian J Surg, 2017, 40(5): 338-344.
19. Phillips DJ, Kutler DI, Kuhel WI. Incidental thyroid nodules in patients with primary hyperparathyroidism. Head Neck, 2014, 36(12): 1763-1765.
20. Bentrem DJ, Angelos P, Talamonti MS, <italic>et al</italic>. Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism? Thyroid, 2002, 12(12): 1109-1112.
21. Vargas-Ortega G, Balcázar-Hernández L, González-Virla B, <italic>et al</italic>. Symptomatic primary hyperparathyroidism as a risk factor for differentiated thyroid cancer. J Thyroid Res, 2018, 2018: 9461079.
22. Wilhelm SM, Wang TS, Ruan DT, <italic>et al</italic>. The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg, 2016, 151(10): 959-968.
23. Hindié E, Zanotti-Fregonara P, Tabarin A, <italic>et al</italic>. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J Nucl Med, 2015, 56(5): 737-744.
24. Pata G, Casella C, Magri GC, <italic>et al</italic>. Financial and clinical implications of low-energy CT combined with <sup>99m</sup>Technetium-sestamibi SPECT for primary hyperparathyroidism. Ann Surg Oncol, 2011, 18(9): 2555-2563.
25. Patel CN, Salahudeen HM, Lansdown M, <italic>et al</italic>. Clinical utility of ultrasound and <sup>99m</sup>Tc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. Clin Radiol, 2010, 65(4): 278-287.
26. Hamidi M, Sullivan M, Hunter G, <italic>et al</italic>. 4D-CT is superior to ultrasound and sestamibi for localizing recurrent parathyroid disease. Ann Surg Oncol, 2018, 25(5): 1403-1409.
27. 中華醫學會外科學分會甲狀腺及代謝外科學組, 中國研究型醫院學會甲狀旁腺及骨代謝疾病專業委員會. 原發性甲狀旁腺功能亢進癥圍手術期處理中國專家共識 (2020版). 中國實用外科雜志, 2020, 40(6): 634-638.
28. Lundstam K, Heck A, Godang K, <italic>et al</italic>. Effect of surgery <italic>versus</italic> observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study). J Bone Miner Res, 2017, 32(9): 1907-1914.
29. Clarke BL. Asymptomatic primary hyperparathyroidism. Front Horm Res, 2019, 51: 13-22.
30. Cansu GB, Y?lmaz N, ?zdem S, <italic>et al</italic>. Parathyroidectomy in asymptomatic primary hyperparathyroidism reduces carotid intima-media thickness and arterial stiffness. Clin Endocrinol (Oxf), 2016, 84(1): 39-47.
31. ?iprová H, Fry?ák Z, Sou?ek M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract, 2016, 22(3): 294-301.
32. Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: a revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery, 2017, 161(1): 16-24.
33. Laird AM, Libutti SK. Minimally invasive parathyroidectomy <italic>versus</italic> bilateral neck exploration for primary hyperparathyroidism. Surg Oncol Clin N Am, 2016, 25(1): 103-118.
34. Norman J, Lopez J, Politz D. Abandoning unilateral parathyroidectomy: why we reversed our position after 15, 000 parathyroid operations. J Am Coll Surg, 2012, 214(3): 260-269.
35. Kavanagh DO, Fitzpatrick P, Myers E, <italic>et al</italic>. A predictive model of suitability for minimally invasive parathyroid surgery in the treatment of primary hyperparathyroidism[corrected]. World J Surg, 2012, 36(5): 1175-1181.
36. Thier M, Daudi S, Bergenfelz A, <italic>et al</italic>. Predictors of multiglandular disease in primary hyperparathyroidism. Langenbecks Arch Surg, 2018, 403(1): 103-109.
37. Najafian A, Kahan S, Olson MT, <italic>et al</italic>. Intraoperative PTH may not be necessary in the management of primary hyperparathyroidism even with only one positive or only indeterminate preoperative localization studies. World J Surg, 2017, 41(6): 1500-1505.
38. Bachar G, Mizrachi A, Hadar T, <italic>et al</italic>. Role of parathyroid hormone monitoring during parathyroidectomy. Head Neck, 2011, 33(12): 1754-1757.
39. Wang W, Kong J, Nie M, <italic>et al</italic>. Primary hyperparathyroidism in Chinese children and adolescents: a single-centre experience at Peking Union Medical College Hospital. Clin Endocrinol (Oxf), 2017, 87(6): 865-873.
40. Hsu SC, Levine MA. Primary hyperparathyroidism in children and adolescents: the Johns Hopkins Children’s Center experience 1984-2001. J Bone Miner Res, 2002, 17(Suppl 2): N44-N50.
41. Mukherjee S, Bhadada SK, Arya AK, <italic>et al</italic>. Primary hyperparathyroidism in the young: comparison with adult primary hyperparathyroidism. Endocr Pract, 2018, 24(12): 1051-1056.
42. Morris LF, Zelada J, Wu B, <italic>et al</italic>. Parathyroid surgery in the elderly. Oncologist, 2010, 15(12): 1273-1284.
43. Hedb?ck G, Odén A. Increased risk of death from primary hyperparathyroidism–an update. Eur J Clin Invest, 1998, 28(4): 271-276.
44. Hu Y, Cui M, Sun Z, <italic>et al</italic>. Clinical presentation, management, and outcomes of primary hyperparathyroidism during pregnancy. Int J Endocrinol, 2017, 2017: 3947423.

Previous Article
原發性甲狀旁腺功能亢進癥診療模式的轉變
Next Article
Analysis of risk factors for lymph node metastasis in T2 stage non-small cell lung cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

原發性甲狀旁腺功能亢進的外科治療進展及展望

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content